This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks Under $3

3. Acadia Pharmaceuticals (ACAD) is a technology-driven biopharmaceutical company focusing on drug discovery and clinical development of treatments for central nervous system disorders.

Net loss for the first quarter of 2011 was $5.8 million or 12 cents per share, compared to a loss of $5.5 million or 14 cents per share in the year-ago quarter. Collaborative revenue totaled $435,000 compared to $2.1 million, following the conclusion of Adadia's collaboration with Biovail in October 2010, when Acadia recognized remaining revenue related to this collaboration.

Cash, cash equivalents and investment securities during the quarter grew to $45.7 million from $37.1 million in the final quarter of 2010. Moreover, the current ratio increased to 7.58 from 6.35 at the end of December 2010, reflecting the company's ability to meet short-term cash requirements.

During April, the company announced extending its drug discovery and development collaboration with Allergan. The alliance is focused on the discovery of new therapeutics for glaucoma and other ophthalmic indications and was formed in March 2003.

Of the two analysts covering the stock, one recommends buying it and the other suggests a hold. There are no sell ratings on the stock. On average, analysts expect 192% upside to $5 in value from current levels.
8 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs